Ignite Creation Date:
2025-12-24 @ 9:22 PM
Ignite Modification Date:
2026-03-04 @ 10:43 PM
Study NCT ID:
NCT02667704
Status:
COMPLETED
Last Update Posted:
2017-04-13
First Post:
2016-01-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Influence of Bosentan on the Pharmacokinetics of Nintedanib
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial was designed to investigate whether, and to which extent, multiple doses of bosentan may influence the plasma levels of nintedanib administered as a single dose.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2015-003819-38 | EUDRACT_NUMBER | EudraCT | View |